SCHEMBL4152126

SCHEMBL4152126

Brc1ccc(-c2cc3cccnn3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.39
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
KDM4E B2RXH2 6/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
ALDH1A1 P00352 4/20 0.39
GAA P10253 3/20 0.39
GALR3 O60755 1/20 0.39
NPY1R P25929 1/20 0.39
STAT3 P40763 1/20 0.39
NPY2R P49146 1/20 0.39
NPC1 O15118 7/20 0.39
RAB9A P51151 7/20 0.39
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
USP8 P40818 1/20 0.37
PARP1 P09874 1/20 0.36
TP53 P04637 2/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10279115 0.80 SMN1; SMN2 (0.46) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL5313274 0.69 MAPT (0.44) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL16417590 0.67 DYRK1A (0.35) MEN1KMT2AKDM4EALDH1A1NPC1
SCHEMBL18751072 0.65 MAPT (0.47) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL18751063 0.65 MAPT (0.50) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL5309811 0.64 NPC1 (0.57) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL4154898 0.63 MAPT (0.49) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL15935253 0.63 GRN (0.35) KDM4EPTGS2
SCHEMBL4043421 0.62 PARP1 (0.41) MAPTMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL27283155 0.62 NPC1 (0.46) MAPTMEN1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS MAPT 4610/4885MEN1 4846/4885KMT2A 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.